Sanofi Consumer Healthcare India Limited has announced its financial results for the quarter ended March 31, 2026. The company reported a Revenue from Operations of ₹2,292 million and a Profit for the period of ₹678 million. Domestic sales demonstrated resilient growth, increasing by 15.5%, while export sales saw significant momentum, growing by 144.4% compared to the same period in the previous year, driven by product relaunches.
Quarterly Financial Highlights
For the quarter ended March 31, 2026, the company achieved a total income of ₹2,348 million. The profit before tax for the period stood at ₹907 million. Earnings per share for the quarter were reported at ₹29.44 (not annualised).
Sales Performance and Strategic Growth
The company’s performance was bolstered by the successful relaunch of key products including Combiflam Suspension, Allegra Suspension, and Depura Kids, which were previously recalled in 2024 as a precautionary measure. Domestic sales showed healthy growth of 15.5%. Export markets also performed exceptionally well, recording a growth of 144.4%, albeit on a lower base compared to the corresponding quarter of the previous year.
Operational Context
The Board of Directors approved these unaudited financial results during their meeting held on April 28, 2026. The meeting, which commenced at 1:00 p.m. and concluded at 3:40 p.m., confirmed that the company continues to operate within a single business segment, the Pharmaceutical Business.
Future Outlook
Looking ahead, the company continues to assess the long-term impact of new labour regulations, having already recognized an incremental financial impact of ₹24 million in the previous year due to changes in wage definitions. The company remains focused on maintaining operational efficiency and supporting its product portfolio to drive sustainable growth in the upcoming fiscal periods.
Source: BSE
